Divarasib explained: did a KRAS G12C lung cancer drug beat existing medicines?

원문 링크: WordPress 원문

SHawn Bio · Drug-development reading

KOR ENG

Did a new lung cancer drug beat existing KRAS G12C medicines? What the numbers do—and do not—show yet

A reader-first take on Roche’s divarasib Phase III announcement: the direction looks positive, but the effect size is still largely unpublished.

This generated image is used as an editorial illustration. Exact numbers and limitations are handled in the text, tables and sources below.

In one sentence: Roche says divarasib showed positive PFS and OS signals versus approved KRAS G12C inhibitors, but median PFS, hazard ratio, ORR and detailed safety data have not yet been released.

The headline can sound simple: a new drug beat existing medicines. For clinical news, however, readers need to separate the direction of the result from the magnitude of the benefit.

Why head-to-head matters

KRASCENDO 1 compared divarasib directly with approved KRAS G12C inhibitors, sotorasib or adagrasib. That makes the question sharper than a single-arm or historical comparison.

The question this study asks

Can a next-generation KRAS G12C inhibitor outperform the first approved KRAS G12C drugs in real comparative testing?

This mid-article image illustrates the clinical-trial flow. It does not encode effect size or response rates.

What is confirmed, and what still needs to wait

The claim boundary is handled directly in the article body, so readers do not need to decode a separate explainer image.

What can be said now

• KRASCENDO 1 is a Phase III head-to-head study.

• The trial included 338 adults.

• Roche reported PFS improvement.

• Roche reported OS statistical significance at interim analysis.

• No new safety signal was reported.

What cannot be said yet

• The median PFS in months

• The hazard ratio and 95% CI

• The median OS

• ORR, DOR and detailed grade ≥3 AE rates

• Regulatory approval or complete replacement of existing drugs

Item What can be read now Caution

PFS Improvement reported Median PFS and HR are unpublished

OS Significance reported at interim analysis Median OS and maturity need confirmation

Safety No new safety signal reported Detailed AE and discontinuation rates need full data

Interpretation Important Phase III signal Do not quantify the benefit yet

The KRAS G12C context

KRAS G12C is an important target in NSCLC. This news is not about the first KRAS G12C drug appearing; it is about whether a next-generation inhibitor can shift the treatment landscape after the first approved agents.

This image provides scientific context. It does not visually claim superiority or approval probability for any specific drug.

When full data arrive, watch: median PFS, HR/CI, OS maturity, comparator-specific outcomes and safety burden. The effect size and uncertainty matter more than a single topline phrase.

Bottom line

The Roche announcement is important. A safe reading is not just “it won,” but also “which numbers are still missing?”

References

• Genentech. Divarasib shows superiority in the Phase III Krascendo 1 trial (1 July 2026).

• ClinicalTrials.gov. Krascendo 1 (NCT06497556).

• Sacher et al. Single-Agent Divarasib in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023;389:710–721. PMID: 37611121.

• Sacher et al. Long-Term Follow-Up of Divarasib in KRAS G12C-Positive NSCLC. J Clin Oncol. 2025. PMID: 40632992.

This article is for scientific interpretation and public education. Divarasib remains investigational; company topline results are not a substitute for a peer-reviewed full report, regulatory review, or medical advice.

다음에 같이 읽기

• KRAS G12C 폐암 신약 divarasib란? 아직 안 보이는 임상 숫자들

• 고형암 CAR-T satri-cel이란? 중국 첫 승인 뉴스의 숫자와 한계

• 비만치료제 읽기